Cellect secures stem cell-based therapy patent

By The Science Advisory Board staff writers

August 6, 2020 -- Cellect Biotechnology has secured a European patent for its stem cell selection technology. The patent was also approved in Australia and Israel, according to the firm.

European patent No. 14851547.1 will expire in October 2034. It covers the regenerative capacity of stem and progenitor cells in the company's Apograft cell-based blood product. Importantly, it protects the intellectual property of the second component of Apograft involving the activation of stem and progenitor cells.

Cellect currently holds 45 patents, it said.

Cellect to develop stem cell therapy for COVID-19
Cellect Biotechnology has inked an agreement with international collaborators to develop a stem cell therapy for COVID-19 disease.

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter